Trastuzumab Emtansine 100 mg injection

Trastuzumab Emtansine 100 mg injection Specification

Origin of Medicine
India

Dosage Form
50 ml

Salt Composition
Trastuzumab Emtansine

Indication
Uses of Ujvira 100mg Injection Ujvira 100mg Injection is indicated for its use in the following conditions: Advanced and metastatic breast cancer

Pacakaging (Quantity Per Box)
50 ml

Drug Type
Injection

Ingredients
Trastuzumab Emtansine

Physical Form
Liquid

Dosage
100 Mg

Dosage Guidelines
As per doctor suggestion

Storage Instructions
2-8 Degree c

Trastuzumab Emtansine 100 mg injection Trade Information

Minimum Order Quantity
100 Packs

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Packs Per Month

Delivery Time
7 Days

Packaging Details
vial

Main Export Market(s)
South America, Asia, Eastern Europe, Central America, North America, Africa, Australia, Middle East, Western Europe

Main Domestic Market
All India

About Trastuzumab Emtansine 100 mg injection

Discription to Ujvira 100mg Injection

Ujvira 100mg Injection is a targeted therapy containing the active constituent trastuzumab emtansine. The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine on February 22, 2013, for treating patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and chemotherapy. This medication is not recommended for adolescents and children under 18. Before taking this medicine, it is vital to inform your doctor if you have any blood clot disorders, liver disorders, or allergies.

Uses of Ujvira 100mg Injection

Ujvira 100mg Injection is indicated for its use in the following conditions:

Advanced and metastatic breast cancer

Therapeutic Effects of Ujvira 100mg Injection

Trastuzumab binds selectively to the HER2 receptors on breast cancer cells' surface, blocks them from receiving growth signals, and stops the cancer cell's growth. DM1 becomes active once the drug enters the cancer cells and helps stop cancer cell growth.

Tell us about your requirement